Schistosomiasis – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Schistosomiasis – Pipeline Review, H2 2019’, provides an overview of the Schistosomiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Schistosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schistosomiasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Schistosomiasis

– The report reviews pipeline therapeutics for Schistosomiasis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Schistosomiasis therapeutics and enlists all their major and minor projects

– The report assesses Schistosomiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Schistosomiasis”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Schistosomiasis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Schistosomiasis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Ebelle Pharmaceuticals Inc

IRBM Science Park SpA

Knight Therapeutics Inc

Merck KGaA

Pai Life Sciences Inc

Tongli Biomedical Co Ltd”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Schistosomiasis Overview

Schistosomiasis Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Schistosomiasis Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Schistosomiasis Companies Involved in Therapeutics Development

IRBM Science Park SpA

Kancera AB

Knight Therapeutics Inc

Merck KGaA

Salvensis

Schistosomiasis Drug Profiles

EDE-1102 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

intestinal schistosomiasis vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

intestinal schistosomiasis vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

L-Praziquantel Drug Profile

Product Description

Mechanism Of Action

R&D Progress

miltefosine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-praziquantel Drug Profile

Product Description

Mechanism Of Action

R&D Progress

schistosomiasis vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Schistosomiasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Schistosomiasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Schistosomiasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Schistosomiasis Dormant Projects

Schistosomiasis Product Development Milestones

Featured News & Press Releases

Jan 18, 2018: George Washington University: Schistosoma vaccine to enter phase Ib clinical trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Table 1: Number of Products under Development for Schistosomiasis, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Universities/Institutes, H2 2019

Table 4: Products under Development by Companies, H2 2019

Table 5: Products under Development by Universities/Institutes, H2 2019

Table 6: Number of Products by Stage and Target, H2 2019

Table 7: Number of Products by Stage and Mechanism of Action, H2 2019

Table 8: Number of Products by Stage and Route of Administration, H2 2019

Table 9: Number of Products by Stage and Molecule Type, H2 2019

Table 10: Schistosomiasis – Pipeline by Ebelle Pharmaceuticals Inc, H2 2019

Table 11: Schistosomiasis – Pipeline by IRBM Science Park SpA, H2 2019

Table 12: Schistosomiasis – Pipeline by Knight Therapeutics Inc, H2 2019

Table 13: Schistosomiasis – Pipeline by Merck KGaA, H2 2019

Table 14: Schistosomiasis – Pipeline by Pai Life Sciences Inc, H2 2019

Table 15: Schistosomiasis – Pipeline by Tongli Biomedical Co Ltd, H2 2019

Table 16: Schistosomiasis – Dormant Projects, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Schistosomiasis, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Targets, H2 2019

Figure 5: Number of Products by Stage and Targets, H2 2019

Figure 6: Number of Products by Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Figure 10: Number of Products by Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports